Survival outcomes of low prostate-specific antigen levels and T stages in patients with high-grade prostate cancer: a population-matched study

Kang, Yongming; Song, Peng; Fang, Kun; Yang, Bo; Yang, Lei; Zhou, Jing; Wang, Linchuan; Dong, Qiang

doi:10.7150/jca.40428

Cited by 6 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors concluded that these highly elevated PSA concentrations suggest the presence of more aggressive or occult metastatic disease, thus indicating that these patients might benefit from more aggressive treatments [ 42 ]. While this relationship between high PSA levels and poor prognosis is especially relevant in PC patients with low or intermediate grade PC, in patients with high grade disease (Gleason score 8–10), lower PSA levels can actually predict a poorer outcome [ 45 , 46 ]; 10% of PC patients with higher grade disease had PSA readings of ≤2.5 ng/mL [ 46 ]. Additionally, reports have indicated that patients who present with PSA levels lower than 4 ng/mL have a greater incidence of distant metastasis than those with PSA concentrations between 4–10 ng/mL, 10–20 ng/mL or >20 ng/mL; Zheng et al inferred that clinicians should pay particular attention to those patients with lower PSA levels, as their disease may be biologically aggressive [ 43 ].…”

Section: Prostate Specific Antigenmentioning

confidence: 99%

Tissue- and Liquid-Based Biomarkers in Prostate Cancer Precision Medicine

Meehan

Gray

Martínez-Pérez

et al. 2021

JPM

View full text Add to dashboard Cite

Worldwide, prostate cancer (PC) is the second-most-frequently diagnosed male cancer and the fifth-most-common cause of all cancer-related deaths. Suspicion of PC in a patient is largely based upon clinical signs and the use of prostate-specific antigen (PSA) levels. Although PSA levels have been criticised for a lack of specificity, leading to PC over-diagnosis, it is still the most commonly used biomarker in PC management. Unfortunately, PC is extremely heterogeneous, and it can be difficult to stratify patients whose tumours are unlikely to progress from those that are aggressive and require treatment intensification. Although PC-specific biomarker research has previously focused on disease diagnosis, there is an unmet clinical need for novel prognostic, predictive and treatment response biomarkers that can be used to provide a precision medicine approach to PC management. In particular, the identification of biomarkers at the time of screening/diagnosis that can provide an indication of disease aggressiveness is perhaps the greatest current unmet clinical need in PC management. Largely through advances in genomic and proteomic techniques, exciting pre-clinical and clinical research is continuing to identify potential tissue, blood and urine-based PC-specific biomarkers that may in the future supplement or replace current standard practices. In this review, we describe how PC-specific biomarker research is progressing, including the evolution of PSA-based tests and those novel assays that have gained clinical approval. We also describe alternative diagnostic biomarkers to PSA, in addition to biomarkers that can predict PC aggressiveness and biomarkers that can predict response to certain therapies. We believe that novel biomarker research has the potential to make significant improvements to the clinical management of this disease in the near future.

show abstract

Section: Prostate Specific Antigenmentioning

confidence: 99%

Tissue- and Liquid-Based Biomarkers in Prostate Cancer Precision Medicine

Meehan

Gray

Martínez-Pérez

et al. 2021

JPM

View full text Add to dashboard Cite

show abstract

“…Prostate cancer (PCa) is one of the most prevalent malignant tumors worldwide and the second largest cause of cancer-related deaths in males (Kang et al, 2020). Its incidence is expected to increase annually with the global trend of population aging (Conti et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

Association between monocyte-to-lymphocyte ratio and prostate cancer in the U.S. population: a population-based study

Wang,

Li,

Liu

et al. 2024

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Introduction:Monocyte-to-lymphocyte ratio (MLR) is a convenient and noninvasive inflammatory biomarker, and inflammation has been reported to be associated with prostate cancer (PCa). Our objective was to ascertain any possible correlation between PCa and MLR.Methods:We utilized data from the 1999–2020 cycles of the National Health and Nutrition Examination Survey (NHANES) regarding MLR and PCa. The independent associations of MLR and other inflammatory biomarkers (platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), system inflammation response index (SIRI), and aggregate index of systemic inflammation (AISI)) with PCa was investigated using weighted multivariate logistic regression and generalized additive models. Receiver operating characteristic (ROC) curves were conducted to evaluate and contrast their diagnostic capabilities.Results:The analysis we conducted comprised 25,367 persons in total. The mean MLR was 0.31 ± 0.14. The prevalence of PCa was 3.1%. A positive association was found between MLR and PCa (OR = 2.28; 95% CI: 1.44, 3.62). According to the interaction tests, age, body mass index (BMI), hypertension, diabetes, and smoking status did not significantly impact the relationship between MLR and PCa (all p for interaction >0.05). ROC analysis showed that MLR had a stronger discriminative ability and accuracy in predicting PCa than other inflammatory biomarkers (NLR, SII, AISI, PLR, and SIRI).Conclusion:MLR might be better than other inflammatory biomarkers (NLR, SIRI, AISI, PLR, and SII) in predicting PCa. American adults who have elevated levels of MLR, NLR, PLR, SII, and AISI should be aware that they have a greater risk of PCa.

show abstract

“…Worldwide, prostate cancer is the second leading cause of cancer-related death among men after lung cancer ( 1 ). The incidence of prostate cancer continued to rise slowly from 2014 through 2018.…”

Section: Introductionmentioning

confidence: 99%

The diagnostic effectiveness of serum sialic acid predicts both qualitative and quantitative prostate cancer in patients with prostate-specific antigen between 4 and 20 ng/mL

Sun,

Yan

2023

Front. Endocrinol.

View full text Add to dashboard Cite

IntroductionThis study aimed to evaluate the predictive value of the serum biochemical index, including alkaline phosphatase (AKP), lactate dehydrogenase (LDH), α-L-fucosidase (AFU), serum sialic acid (SA), and fibrinogen (FIB), for prostate cancer (PCa) and clinically significant prostate cancer (CSPCa) in patients with a prostate-specific antigen (PSA) value between 4 and 20 ng/mL.Patients and methodsThis study retrospectively examined the clinical data of 408 eligible patients who underwent prostate biopsies in our hospital between March 2015 and July 2022. CSPCa was defined as a “Gleason grade group of≥2”. For analyzing the association between PCa/CSPCa and serum biochemical index, univariable logistic regression and multivariable logistic regression were conducted. Based on the multivariable logistic regression model, we constructed models and compared the area under the curve (AUC). We generated the nomogram, the ROC curve, the DCA curve, and the calibration curve for PCa.ResultsOverall, we studied 271 patients with PCa (including 155 patients with CSPCa) and 137 non-PCa patients. Patients with PCa were more likely to consume alcohol, have higher total PSA (TPSA) values, and have lower free PSA (FPSA) and free/total PSA (f/T) values. There were higher TPSA values and lower f/T values in the CSPCa group when compared with the non-CSPCa group. The univariate logistic regression analyses did not show significant results. However, AKP, AFU, SA, TPSA, and FPSA all retain significant significance when all factors are included in multifactor logistic regression analysis. This finding suggests that the exposure factor exhibited an independent effect on the outcome after controlling for other factors, including the potential confounding effects that may have been underestimated. Through ROC curves, we found that SA and TPSA levels are more powerful predictors. In contrast, there is a lack of excellent predictive value for PCA and CSPCa using Age, AFU, FIB, and FPSA.ConclusionIn our study, serum biochemical index is a potential prediction tool for PCa and CSPCa for patients with PSA values between 4 and 20 ng/mL. Additionally, the new serum biochemical index SA is also useful when diagnosing PCa and CSPCa, as we conclude in our study.

show abstract

Survival outcomes of low prostate-specific antigen levels and T stages in patients with high-grade prostate cancer: a population-matched study

Cited by 6 publications

References 21 publications

Tissue- and Liquid-Based Biomarkers in Prostate Cancer Precision Medicine

Tissue- and Liquid-Based Biomarkers in Prostate Cancer Precision Medicine

Association between monocyte-to-lymphocyte ratio and prostate cancer in the U.S. population: a population-based study

The diagnostic effectiveness of serum sialic acid predicts both qualitative and quantitative prostate cancer in patients with prostate-specific antigen between 4 and 20 ng/mL

Contact Info

Product

Resources

About